Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year over year increase. The oncology and COVID-19 products were primary ...

At Least $4 Billion Anticipated by End of 2024 from Cost Realignment Program(5) Approximately $1.5 Billion Expected by End of 2027 from First Phase of Manufacturing Optimization Program Pfizer Inc ...